

Chi Chiu Mok

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8950491/chi-chiu-mok-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187 papers	4,533 citations	41 h-index	60 g-index
215 ext. papers	5,406 ext. citations	4.4 avg, IF	6.23 L-index

#	Paper	IF	Citations
187	Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2774-82		164
186	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019 , 95, 268-280	9.9	145
185	Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2559-68		136
184	Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. <i>Medicine (United States)</i> , 2005 , 84, 218-224	1.8	135
183	Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 659-64	2.4	134
182	Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 30-6	2.4	130
181	Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. <i>Arthritis Care and Research</i> , 2011 , 63, 195-202	4.7	130
180	Biomarkers for lupus nephritis: a critical appraisal. <i>Journal of Biomedicine and Biotechnology</i> , 2010 , 2010, 638413		111
179	Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. <i>Kidney International</i> , 2005 , 68, 813-7	9.9	109
178	Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. <i>American Journal of Medicine</i> , 2006 , 119, 355.e25-33	2.4	108
177	Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. <i>American Journal of Kidney Diseases</i> , 1999 , 34, 315-23	7.4	97
176	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019 , 95, 281-295	9.9	87
175	Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. <i>Rheumatology</i> , 2012 , 51, 644-52	3.9	81
174	Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. <i>Lupus</i> , 2012 , 21, 36-42	2.6	80
173	Rituximab for the treatment of rheumatoid arthritis: an update. <i>Drug Design, Development and Therapy</i> , 2013 , 8, 87-100	4.4	78
172	Damage accrual in southern Chinese patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2003 , 30, 1513-9	4.1	68
171	Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese. <i>Lupus</i> , 2011 , 20, 767-76		66

170	Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. <i>American Journal of Medicine</i> , 2003 , 115, 59-62	2.4	66
169	Prevalence and determinants of psychiatric disorders in patients with rheumatoid arthritis. <i>Psychosomatics</i> , 2010 , 51, 338-338.e8	2.6	64
168	The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. <i>PLoS ONE</i> , 2017 , 12, e0175207	3.7	63
167	Rituximab for refractory polymyositis: an open-label prospective study. <i>Journal of Rheumatology</i> , 2007 , 34, 1864-8	4.1	62
166	Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. <i>Journal of Rheumatology</i> , 2008 , 35, 1978-82	4.1	59
165	Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. <i>American Journal of Kidney Diseases</i> , 2004 , 43, 269-76	7.4	58
164	Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis. <i>Arthritis Care and Research</i> , 2016 , 68, 1295-302	4.7	58
163	Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. <i>Bone</i> , 2015 , 75, 222-8	4.7	56
162	Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1420-1425	2.4	55
161	Vitamin D and systemic lupus erythematosus: an update. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 453-63	5.1	52
160	Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 778-84	2.4	51
159	Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2010 , 39, 42-9	1.9	50
158	Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2009 , 38, 362-8	1.9	49
157	Overview of lupus nephritis management guidelines and perspective from Asia. <i>Nephrology</i> , 2014 , 19, 11-20	2.2	48
156	Calcineurin inhibitors in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 429-438	5.3	46
155	Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. <i>Nature Reviews Nephrology</i> , 2009 , 5, 212-20	14.9	46
154	Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. <i>Lupus</i> , 2013 , 22, 1135-41	2.6	45
153	Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. <i>Journal of Rheumatology</i> , 2008 , 35, 172-4	4.1	45

152	Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. <i>Arthritis Care and Research</i> , 2011 , 63, 875-83	4.7	44
151	Therapeutic options for resistant lupus nephritis. <i>Seminars in Arthritis and Rheumatism</i> , 2006 , 36, 71-81	5.3	43
150	Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. <i>Medicine (United States)</i> , 2006 , 85, 221-228	1.8	43
149	Mycophenolate mofetil in lupus glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2002 , 40, 447-574	5.4	43
148	Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. <i>American Journal of Medicine</i> , 2004 , 117, 791-5	2.4	43
147	The Jakinibs in systemic lupus erythematosus: progress and prospects. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 85-92	5.9	41
146	Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. <i>Lupus</i> , 2008 , 17, 1103-7	2.6	40
145	Current role of rituximab in systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 154-63	2.3	37
144	Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. <i>Lupus</i> , 2009 , 18, 1091-5	2.6	37
143	Concurrent psychiatric disorders are associated with significantly poorer quality of life in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2012 , 41, 253-9	1.9	36
142	High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2013 , 65, 441-7	4.7	34
141	Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. <i>Translational Research</i> , 2010 , 156, 320-5	11	34
140	Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. <i>Bone</i> , 2008 , 43, 327-331	4.7	34
139	Investigations and management of gastrointestinal and hepatic manifestations of systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 741-66	5.3	34
138	Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3997-4002		33
137	Suicidal ideation in patients with systemic lupus erythematosus: incidence and risk factors. <i>Rheumatology</i> , 2014 , 53, 714-21	3.9	31
136	Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. <i>Scandinavian Journal of Rheumatology</i> , 2003 , 32, 181-3	1.9	30
135	Mycophenolate mofetil for lupus nephritis: an update. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 1353-64	5.1	29

134	Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. <i>Clinical Rheumatology</i> , 2011 , 30, 303-12	3.9	29
133	Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 201-11	5.4	28
132	Prevalence and risk factors of low bone mineral density in Chinese patients with systemic sclerosis: a case-control study. <i>Rheumatology</i> , 2013 , 52, 296-303	3.9	28
131	Overview of lupus nephritis management guidelines and perspective from Asia. <i>International Journal of Rheumatic Diseases</i> , 2013 , 16, 625-36	2.3	25
130	Association of CD247 with systemic lupus erythematosus in Asian populations. <i>Lupus</i> , 2012 , 21, 75-83	2.6	24
129	Understanding lupus nephritis: diagnosis, management, and treatment options. <i>International Journal of Women's Health</i> , 2012 , 4, 213-22	2.8	24
128	Mucormycosis in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2003 , 33, 115-24	5.3	24
127	Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus. <i>Journal of Autoimmunity</i> , 2019 , 96, 59-73	15.5	24
126	Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2015 , 67, 297-304	4.7	23
125	Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. <i>Vaccine</i> , 2018 , 36, 3301-3307	4.1	23
124	Association of depressive/anxiety symptoms with quality of life and work ability in patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 389-95	2.2	23
123	Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016 , 68, 1303-9	4.7	22
122	Rheumatoid-like polyarthritis as a presenting feature of metastatic carcinoma: a case presentation and review of the literature. <i>Clinical Rheumatology</i> , 2003 , 22, 353-4	3.9	22
121	Behçet's disease in southern Chinese patients. <i>Journal of Rheumatology</i> , 2002 , 29, 1689-93	4.1	22
120	Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis. <i>Arthritis Research and Therapy</i> , 2018 , 20, 6	5.7	21
119	Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 35-41	5.1	21
118	Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups. <i>Nature Communications</i> , 2021 , 12, 772	17.4	21
117	Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. <i>Nature Communications</i> , 2020 , 11, 2197	17.4	20

116	Neuro-ophthalmologic manifestations of systemic lupus erythematosus: a systematic review. <i>International Journal of Rheumatic Diseases</i> , 2014 , 17, 494-501	2.3	20
115	Minimal mesangial lupus nephritis: a systematic review. <i>Scandinavian Journal of Rheumatology</i> , 2010 , 39, 181-9	1.9	20
114	Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study. <i>Medicine (United States)</i> , 2007 , 86, 203-209	1.8	20
113	Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 891-8	2.4	19
112	Metabolic syndrome and systemic lupus erythematosus: the connection. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 765-775	5.1	19
111	Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial. <i>Scandinavian Journal of Rheumatology</i> , 2015 , 44, 480-6	1.9	19
110	Emerging biological therapies for systemic lupus erythematosus. <i>Expert Opinion on Emerging Drugs</i> , 2014 , 19, 303-22	3.7	19
109	Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus: a cohort study. <i>Medicine (United States)</i> , 2013 , 92, 217-222	1.8	18
108	Con: Cyclophosphamide for the treatment of lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1053-7	4.3	18
107	Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 677-692	5.1	15
106	Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus. <i>Lupus</i> , 2017 , 26, 715-722	2.6	15
105	Update on emerging drug therapies for systemic lupus erythematosus. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 53-70	3.7	15
104	Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1070-1076	2.4	15
103	Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1561-6	4.3	15
102	Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 337	2.8	14
101	Herpes zoster vaccination in systemic lupus erythematosus: the current status. <i>Human Vaccines and Immunotherapeutics</i> , 2019 , 15, 45-48	4.4	14
100	Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial. <i>Lupus</i> , 2013 , 22, 1470-8	2.6	14
99	Childhood-onset disease carries a higher risk of low bone mineral density in an adult population of systemic lupus erythematosus. <i>Rheumatology</i> , 2012 , 51, 468-75	3.9	14

98	Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2010 , 29, 599-604	3.9	14
97	Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages. <i>Frontiers in Immunology</i> , 2020 , 11, 671	8.4	13
96	Erythema elevatum diutinum in systemic lupus erythematosus. <i>Rheumatology International</i> , 2011 , 31, 259-62	3.6	13
95	Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019 , 71, 1647-1652	4.7	13
94	Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus. <i>Lupus</i> , 2008 , 17, 1018-22	2.6	12
93	Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. <i>Clinical Rheumatology</i> , 2019 , 38, 3331-3350	3.9	11
92	Serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus: a longitudinal cohort analysis. <i>Clinical Rheumatology</i> , 2018 , 37, 2685-2692	3.9	11
91	Gene-based meta-analysis of genome-wide association study data identifies independent single-nucleotide polymorphisms in ANXA6 as being associated with systemic lupus erythematosus in Asian populations. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2966-77	9.5	11
90	Factors associated with withdrawal of the anti-TNF biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry. <i>International Journal of Rheumatic Diseases</i> , 2014 , 17 Suppl 3, 1-8	2.3	11
89	Scleroderma renal crisis sine scleroderma during pregnancy. <i>Scandinavian Journal of Rheumatology</i> , 2003 , 32, 55-7	1.9	11
88	Treat-to-target in systemic lupus erythematosus: are we there yet?. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 675-80	3.8	10
87	Identification of Low-Abundance Urinary Biomarkers in Lupus Nephritis Using Electrochemiluminescence Immunoassays. <i>Arthritis and Rheumatology</i> , 2019 , 71, 744-755	9.5	10
86	Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1663-1668	2.4	9
85	Effect of the metabolic syndrome on organ damage and mortality in patients with systemic lupus erythematosus: a longitudinal analysis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 389-395	2.2	9
84	Trend of Survival of a Cohort of Chinese Patients With Systemic Lupus Erythematosus Over 25 Years. <i>Frontiers in Medicine</i> , 2020 , 7, 552	4.9	7
83	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. <i>Lancet Rheumatology</i> , 2021 ,	14.2	7
82	Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 767-780	5.3	7
81	Management of glucocorticoid-related osteoporotic vertebral fracture. <i>Osteoporosis and Sarcopenia</i> , 2020 , 6, 1-7	2.3	6

80	Update on B-cell targeted therapies for systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 773-88	5.4	6
79	Emerging drug therapies for systemic lupus erythematosus. <i>Expert Opinion on Emerging Drugs</i> , 2006 , 11, 597-608	3.7	6
78	Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015 , 17, 67	5.7	5
77	Moyamoya phenomenon in systemic lupus erythematosus. <i>Rheumatology</i> , 2011 , 50, 1931	3.9	5
76	Systemic lupus erythematosus: what should family physicians know in 2018?. <i>Hong Kong Medical Journal</i> , 2018 , 24, 501-511	0.7	5
75	Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial. <i>Bone</i> , 2021 , 146, 115902	4.7	5
74	The importance of assessment and management of morning stiffness in Asian patients with rheumatoid arthritis: Recommendations from an expert panel. <i>International Journal of Rheumatic Diseases</i> , 2016 , 19, 30-7	2.3	5
73	Prevalence and Determinants of Psychiatric Disorders in Patients With Rheumatoid Arthritis. <i>Psychosomatics</i> , 2010 , 51, 338-338.e8	2.6	4
72	Management of systemic lupus erythematosus in Chinese patients. <i>Expert Review of Clinical Immunology</i> , 2007 , 3, 925-35	5.1	4
71	Morning Stiffness in Elderly Patients with Rheumatoid Arthritis: What is Known About the Effect of Biological and Targeted Agents?. <i>Drugs and Aging</i> , 2018 , 35, 477-483	4.7	3
70	Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice?. <i>Current Rheumatology Reviews</i> , 2019 , 15, 2-6	1.6	3
69	Clinical presentation, treatment and outcome of Takayasu's arteritis in southern Chinese: a multicenter retrospective study. <i>Rheumatology International</i> , 2018 , 38, 2263-2270	3.6	3
68	Systemic lupus erythematosus: Withdrawing standard of care therapies in SLE trials?. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 328-330	8.1	2
67	Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies. <i>Lupus</i> , 2020 , 29, 836-844	2.6	2
66	Therapeutic advances in rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , 2004 , 7, 62-70		2
65	Non-tumor necrosis factor biological therapies for rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , 2005 , 8, 77-83		2
64	The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses.. <i>Journal of Clinical Investigation</i> , 2022 , 132,	15.9	2
63	The Hong Kong Society of Rheumatology Consensus Recommendations for COVID-19 Vaccination in Adult Patients with Autoimmune Rheumatic Diseases. <i>Journal of Clinical Rheumatology and Immunology</i> , 2021 , 21, 7-14	0	2

62	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. <i>International Journal of Rheumatic Diseases</i> , 2021 , 24, 880-895	3.3	2
61	Drivers of Satisfaction With Care for Patients With Lupus. <i>ACR Open Rheumatology</i> , 2019 , 1, 649-656	3.5	2
60	Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in ANA-positive Chinese patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X2211003	3.8	2
59	LB001 EFFICACY AND SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A PHASE 3, RANDOMISED, PLACEBO-CONTROLLED TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35,	4.3	1
58	Intercorrelation between MRI disease activity scores of the sacroiliac joints and the spine, and clinical disease activity indices in patients with axial spondyloarthritis. <i>Reports in Medical Imaging</i> , 2017 , Volume 10, 45-51	0.8	1
57	Management of Psychosis in Neuropsychiatric Lupus. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019 , 19, 9-17	0	1
56	Clinical Usefulness of HLA-B*58:01 Genotyping in Gouty Arthritis. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019 , 19, 27-33	0	1
55	EULAR recommendations for the management of rheumatoid arthritis: what is new in 2017 and its applicability in our local setting. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017 , 17, 47-52		1
54	THU0308 Use of Complementary and Alternative Medicine (CAM) in Chinese Patients with Rheumatic Diseases: Prevalence and Associated Demographic, Clinical and Social Factors. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 307.2-308	2.4	1
53	SAT0216 Relationship between individual organ damage and mortality of systemic lupus erythematosus (SLE): A prospective cohort study of 679 patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 545.1-545	2.4	1
52	Biological therapies for rheumatoid arthritis: beyond TNF- α blockade. <i>APLAR Journal of Rheumatology</i> , 2006 , 9, 200-205		1
51	COVID-19 and Rheumatic Diseases: Practical Issues. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020 , 20, 21-24	0	1
50	Posterior reversible encephalopathy syndrome as a neuropsychiatric manifestation of systemic lupus erythematosus. <i>Hong Kong Medical Journal</i> , 2019 , 25, 410-412	0.7	1
49	The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (May 2017). <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017 , 17, 29-32		1
48	Therapeutic Plasma Exchange in Patients with Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020 , 20, 65-70	0	1
47	The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (May 2018). <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2018 , 18, 30-34		1
46	Human Complement C4B Allotypes and Deficiencies in Selected Cases With Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2021 , 12, 739430	8.4	1
45	Who should treat lupus nephritis: rheumatologists or nephrologists?. <i>Nature Clinical Practice Nephrology</i> , 2008 , 4, E1		1

44	A Consensus for the Management of Systemic Lupus Erythematosus in Asia. <i>Journal of Clinical Rheumatology and Immunology</i> , 2021 , 21, 1-6	O	1
43	FRI0305 Factors Determining Hydroxychloroquine Serum Levels in A Cohort of Chinese Patients with Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 545.3-546	2.4	1
42	Imaging Pattern and Outcome of Stroke in Patients With Systemic Lupus Erythematosus: A Case-control Study. <i>Journal of Rheumatology</i> , 2021 , 48, 533-540	4.1	1
41	The dawn of a new era of therapies in systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , 2020 , 1, 31-37	O.2	O
40	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1052	4.3	
39	SAT0020 Cross Cultural Adaptation and Validation of Lupuspro in Southern Chinese Patients with Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 596.2-596	2.4	
38	FRI0397 Relationship between Igg Anti-Nr2 Glutamate Receptor Antibodies and Depressive/Anxiety Symptoms in Patients with Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 531.1-531	2.4	
37	SAT0019 Effect of Depressive/Anxiety Symptoms on Quality of Life and Work Disability in Patients with Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 596.1-596	2.4	
36	Diagnosis and treatment of primary Sjogren's syndrome: an update. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017 , 17, 6-11		
35	OP0264 Factors Associated with Renal Remission, Relapse and Long-Term Renal Function Decline in Lupus Nephritis Treated with Combined Prednisolone and Mycophenolate Mofetil (MMF) or Tacrolimus (TAC). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 171.3-172	2.4	
34	FRI0393 Standardized Incidence Ratio (SIR), time Trend and Risk Factors of Avascular Bone Necrosis (AVN) in Patients with Systemic Lupus Erythematosus (SLE). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 569.2-569	2.4	
33	SAT0394 Can Immunosuppressive Drug Treatment Reduce Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Propensity Score Analysis of a Longitudinal Cohort of 803 Patients?. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 801.3-802	2.4	
32	AB0558 Association of the Metabolic Syndrome (Mets) with Vascular Complications, End Stage Renal Failure (ESRF) and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Cohort Analysis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1086.3-1087	2.4	
31	FRI0392 Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 569.1-569	2.4	
30	FRI0417 Standardized incidence ratios (SIRS) and risk factors of suicide in chinese patients with rheumatic diseases in hong kong: 1999-2010. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 455.1-455	2.4	
29	AB0646 Serum hepcidin level in systemic lupus erythematosus (SLE): Relationship with disease activity, organ damage and coronary atherosclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 675.14-675	2.4	
28	THU0003 Effect of Renal Damage on Extra-Renal Organ Damage and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Longitudinal Cohort Study of 756 Patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 177.3-177	2.4	
27	THU0170 The effect of the antiphospholipid syndrome (APS) on survival in 679 patients with sle: A prospective study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 213.1-213	2.4	

26	FRI0252 Severity of skin, tendon and joint damage in chinese patients with systemic sclerosis (SSC) is associated with higher disability and poorer health-related quality of life: A case-control study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 399.3-399	2.4
25	THU0243 Standardized mortality ratios and predictors of survival in 215 southern chinese patients with inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 237.2-237	2.4
24	SAT0215 Clinical presentation, treatment and outcome of membranous nephropathy in SLE: A comparison with proliferative lupus glomerulonephritis in 141 patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 544.3-545	2.4
23	AB0453 Retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and predictive factors for drug withdrawal: Data from the hong kong biologics registry. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 663.9-663	2.4
22	AB0645 Suicidal ideation in patients with systemic lupus erythematosus: Incidence and relationship with anxiety/depression score, disease activity and organ damage. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 675.13-675	2.4
21	Estimation of fracture risk by the FRAX tool in patients with systemic lupus erythematosus: a 10-year longitudinal validation study.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X221074451	2.8
20	Glucocorticoid Withdrawal in Lupus Nephritis: A Study Protocol and Literature Review. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020 , 20, 47-55	0
19	The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (November 2017). <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017 , 17, 71-75	
18	A young lady with inflammation of unknown origin. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2018 , 18, 67-71	
17	The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (Nov 2018). <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2018 , 18, 77-80	
16	Management of immune-related adverse events in patients treated with immune checkpoint inhibitorsRheumatology point of view. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2018 , 18, 56-60	
15	The 2019 Updated Hong Kong Society of Rheumatology Consensus Statements for the Management of Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019 , 19, 43-46 ^O	
14	Update on Symptomatic Treatment of Acute Vertebral Compression Fracture. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019 , 19, 47-52	0
13	Cyclophosphamide Versus Obinutuzumab for the Treatment of Anti-MDA5 Positive Inflammatory Myopathy with Interstitial Lung Disease: A Study Protocol and LiteratureReview. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019 , 19, 53-58	0
12	The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (December 2016). <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2016 , 16, 57-60	
11	Dissonance between physiciansand patients perspectives on managing impaired morning function in Asian patients with rheumatoid arthritis. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017 , 17, 18-25	
10	Rheumatology Drugs and COVID-19. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020 , 20, 1-3	0
9	Response to: 'Correspondence on 'Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis' by Xu. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4

- 8 Glucocorticoid-Induced Osteoporosis: The Potential Role of Romosozumab. *Journal of Clinical Rheumatology and Immunology*, **2020**, 20, 71-79 0
- 7 A new old treatment for lupus nephritis. *Lancet, The*, **2021**, 397, 2027-2029 40
- 6 Pseudo-Pelger-Huë Nuclear Anomaly in Systemic Lupus Erythematosus. *Arthritis and Rheumatology*, **2016**, 68, 2513 9.5
- 5 SAT0296 Is Hyperuricemia An Independent Risk Factor for Arterial Thrombosis in Systemic Lupus Erythematosus?. *Annals of the Rheumatic Diseases*, **2016**, 75, 775.2-775 2.4
- 4 Gastrointestinal, hepatic, and pancreatic disorders in systemic lupus erythematosus **2021**, 439-449
- 3 Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. *Lupus*, **2021**, 30, 1790-1798 2.6
- 2 Biologics in Systemic Lupus Erythematosus (SLE) **2022**, 61-73
- 1 Osteoporosis in Rheumatic Diseases. *Journal of Clinical Rheumatology and Immunology*, 1-8 0